P2.06-05 Durvalumab ± Tremelimumab + Chemotherapy in 1L Metastatic NSCLC: Characterisation of patients with PFS ≥12 months in POSEIDON
| Autor: | Cho, B.C., Diaz Perez, I., Lowery, C., Szadkowski, L., Peters, S., Garon, E.B., Mok, T., Johnson, M.L. |
|---|---|
| Zdroj: | Journal of Thoracic Oncology; November 2023, Vol. 18 Issue: 11, Number 11 Supplement 1 pS318-S319, 2p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|